iShares Genomics Immunology and Healthcare ETF

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Moderna President Stephen Hoge Sells 53,336 Shares at $48.4 and Exercises Options

Truist Financial Cuts Regeneron Price Target, Sending Shares Gap Down

Merck Plans to Issue $6 Billion in Bonds to Fund Terns Pharmaceutical Acquisition

Regeneron's fianlimab combination fails Phase 3, shares plunge over 11%

Regeneron Partners with Parabilis for $125M Deal to Advance Antibody Conjugates

Merck Announces Experimental Endometrial Cancer Drug Meets Primary Endpoint in Late-Stage Trial

Revolution Medicines Pancreatic Cancer Drug Trial Shows Positive Results, US Cancer Center Launches Expanded Access Plan Amid Stock Fluctuation

Moderna Stock Surges 13% Amid Hantavirus Outbreak; Analysts Cite Limited Commercialization Potential

Regeneron Provides Update on Phase 3 Trial of Fianlimab Combination for Melanoma

Allworth Financial LP Increases Merck Holdings by 71.4%

US Clinics Race to Enroll Patients in Revolution Medicines Pancreatic Cancer Drug Early Access Plan After FDA Approval

Arbutus Biopharma reports Q1 2026 net income of $169.7 million

Moderna Recognized for mRNA Achievements and Approved for Flu and COVID Combo Vaccine

Amundi Increases Stake in Merck Above 3% Threshold

Bayer Aktiengesellschaft released FY2026 Q1 earnings on May 12 Pre-Market EST, actual revenue USD 15.36 B (forecast USD 15.49 B), actual EPS USD 3.2202

Bernstein Analyst Reiterates Neutral Rating on Moderna

Merck Shows Latest Progress in Its Oncology Portfolio

Roche Launches New Blood Test for Alzheimer's Pathology with CE Certification

Moderna Presents mRNA-4359 Cancer Antigen Therapy Study Results

Amesite

InMed Pharmaceuticals

Meiwu Tech

Generation Income Properties

Co-Diagnostics

Phoenix Asia

MetaVia

BAYVIEW ACQUISITION CORPORATION COM USD0.0001 (S/R) 17/11/2028

NextNRG

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

GRAL

LABU

IDNA

SBIO

ARKG

Grail's Medicare study reveals that emergency department (ED) involvement at initial cancer diagnosis leads to higher first-year healthcare costs. Analyzing 818,120 beneficiaries from 2010-2020, the study found that 26.6% had ED involvement, accounting for 39% of total healthcare costs post-diagnosis. Mean costs were USD 88,315 for ED cases versus USD 62,813 for non-ED cases, with significant costs driven by inpatient hospitalizations. Incremental costs varied by cancer type, reaching USD 104,862 for leukemia.

PUBT

GRAIL

Proshares Ultra Nasdaq Biotech

SPDR S&P Health Equip

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

ALPS Medical Breakthrough

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

iShares US Healthcare Providers

VanEck Biotech ETF

iShares US Medical Devices

Grail posts Medicare study on ED-linked cancer diagnoses, higher costs

MEDP

A class action lawsuit has been filed against Medpace Holdings Inc. for securities fraud, alleging misrepresentations regarding cancellation rates and book-to-bill ratios, leading to a 16% stock drop. Investors are urged to act by June 8, 2026, to be appointed as lead plaintiffs. The case is pending in the U.S. District Court for the Southern District of Ohio.

prnewswire

Medpace

Direxion S&P Biotech Bear 3X

Tesla

Teva Pharmaceutical Industries

06:13 ETMEDP Deadline Alert: Medpace Investors with Losses are Notified of the Pending Securities Fraud Class Action Over Alleged Misrepresentations

IDXX

IDEXX Laboratories Inc. (IDXX) shares rose 3.21% to $545.79 on a mixed trading day, while the Dow Jones increased by 0.32% and the S&P 500 fell by 0.07%. Despite the gain, IDXX remains 29.12% below its 52-week high of $769.98. Competitors like Johnson & Johnson, Medtronic, and Boston Scientific also saw stock increases, with Boston Scientific leading at 6.15%. Trading volume for IDXX was 633,490, surpassing its 50-day average of 559,521.

MarketWatch Automated

IDEXX Labs

IDEXX Laboratories Inc. Stock Outperforms Competitors On Strong Trading Day

Guardant Health, Inc. announced the approval of restricted stock units (RSUs) for 267 new non-executive employees, totaling 143,898 shares, under the 2023 Employment Inducement Incentive Award Plan. The RSUs, granted as inducements for employment, will vest annually over three years. This action complies with Nasdaq Listing Rule 5635(c)(4).

StockTitan

Guardant Health

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GH Stock News

Elyxium Wealth LLC has invested $3.67 billion in IDEXX Laboratories, acquiring 5,419,507 shares, which now represent 54.3% of its portfolio. Other institutional investors have also increased their stakes in IDEXX. The company's stock opened at $528.79, with a market cap of $41.71 billion and a P/E ratio of 38.94. IDEXX reported a quarterly EPS of $3.47, exceeding estimates, and has set FY 2026 guidance at 14.450-14.900 EPS.

Market Beat

Bank of NY Mellon

Invesco

Principal Financial

Citigroup

BANK OF NEW YORK MELLON CORP DEP SHS REPG 1/4000TH INT SER K PFD

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Elyxium Wealth LLC Invests $3.67 Billion in IDEXX Laboratories, Inc. $IDXX

World Investment Advisors acquired a new stake in Guardant Health, Inc. (NASDAQ:GH) by purchasing 16,290 shares valued at approximately $1.66 million in Q4. Other investors, including AQR Capital Management and Sei Investments, also increased their holdings. Guardant Health's stock opened at $94.92, with a market cap of $12.59 billion. The company reported a quarterly revenue of $281.27 million, up 39.4% year-over-year, but missed EPS estimates. Analysts have mixed ratings, with a consensus price target of $129.42.

SEI Investments

Manulife Financial

Raymond James Financial

Barclays

UBS Group AG

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

World Investment Advisors Purchases New Position in Guardant Health, Inc. $GH

Robbins Geller Rudman & Dowd LLP announces that investors of Medpace Holdings Inc. who suffered losses between April 22, 2025, and February 9, 2026, can seek to be lead plaintiffs in a class action lawsuit. The lawsuit alleges violations of the Securities Exchange Act, including misleading statements about the company's book-to-bill ratio. Interested investors must apply by June 8, 2026.

PR Newswire

INVESTOR NOTICE: Medpace Holdings Inc. (MEDP) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek | CAI Stock News

Caris Life Sciences

Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek | CAI Stock News

Pomerantz Law Firm is investigating claims on behalf of investors of GeneDx Holdings Corp. (NASDAQ: WGS) regarding potential securities fraud or unlawful business practices by the company and its officers. GeneDx recently reported Q1 2026 financial results, revealing total revenue of $102.3 million but reduced its full-year revenue guidance to $475-$490 million, down from $540-$555 million. Following this news, GeneDx's stock price plummeted by 49.20% to $34.51 per share on May 5, 2026. Investors are encouraged to contact Pomerantz for more information.

GeneDx

GeneDx - CW27

20:02 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS

IBBQ

Charles River Laboratories International Inc. (CRL) shares fell 2.29% to $159.12 on Thursday, marking the second consecutive day of losses. This decline occurred despite a positive trading session for the overall market, with the S&P 500 and Dow Jones rising. CRL's stock is currently 30.48% below its 52-week high of $228.88. In comparison, competitors Labcorp Holdings, Alnylam Pharmaceuticals, and Bio-Techne showed mixed performance. Trading volume was below the 50-day average.

Charles River Laboratorie

Invesco Nasdaq Biotechnology ETF

Labcorp

Alnylam Pharma

Bio-Techne

S&P 500

Dow Jones Industrial Average

Charles River Laboratories International Inc. Stock Underperforms Thursday When Compared To Competitors

iShares Genomics Immunology and Healthcare ETF(IDNA.US)

Grail posts Medicare study on ED-linked cancer diagnoses, higher costs

06:13 ETMEDP Deadline Alert: Medpace Investors with Losses are Notified of the Pending Securities Fraud Class Action Over Alleged Misrepresentations

IDEXX Laboratories Inc. Stock Outperforms Competitors On Strong Trading Day

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GH Stock News

Elyxium Wealth LLC Invests $3.67 Billion in IDEXX Laboratories, Inc. $IDXX